# Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

> **NCT05173298** · — · UNKNOWN · sponsor: **CHA University** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** atezolizumab plus bevacizumab

## Key facts

- **NCT ID:** NCT05173298
- **Lead sponsor:** CHA University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-02
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05173298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05173298, "Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05173298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*